ArticleScientific reports2018
Field validation of recombinant antigen immunoassays for diagnosis of Lassa fever.
Article in Scientific reports, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 2 syntheses or guidelines pooled it, 52 citations in OpenAlex.
- Clinical characterization of Lassa fever: A systematic review of clinical reports and research to inform clinical trial design.PLoS neglected tropical diseases · 2021Pooled it
- Sensitivity and specificity of diagnostic tests for Lassa fever: a systematic review.BMC infectious diseases · 2019Pooled it
- Biosecurity and Diagnosis of Viral Hemorrhagic Fevers: Strategic Considerations for Military Medicine.Diagnostics (Basel, Switzerland) · 2026Review
- Development of a broad-lineage Lassa virus rapid diagnostic test informed by the WHO REASSURED framework.Journal of clinical microbiology · 2026Article
- Development of novel monoclonal antibodies for detection of pan-Lassa virus.PLoS neglected tropical diseases · 2026Article
- Development of a Rapid Diagnostic Test to Distinguish between Emerging Viruses That Cause Hemorrhagic Fever.The American journal of tropical medicine and hygiene · 2025Article
- Evaluation of antigen and antibody assays for surveillance of Lassa virus in peri-domestic rodents in southeastern Sierra Leone: a cross-sectional study.The Lancet. Microbe · 2025Article
- Evaluation of the diagnostic accuracy of the ReLASV Pan-Lassa Antigen Rapid Test for Lassa Fever in Nigeria.PLOS global public health · 2025Article
- Lassa fever in Nigeria: epidemiology and risk perception.Scientific reports · 2024Article
- Genome-wide association study identifies human genetic variants associated with fatal outcome from Lassa fever.Nature microbiology · 2024Article
- Metagenomic surveillance uncovers diverse and novel viral taxa in febrile patients from Nigeria.Nature communications · 2023Article
- Machine learning for design of degenerate Cas13a crRNAs using lassa virus as a model of highly variable RNA target.Scientific reports · 2023Article
- Seroprevalence of anti-Lassa Virus IgG antibodies in three districts of Sierra Leone: A cross-sectional, population-based study.PLoS neglected tropical diseases · 2023Article
- 50 Years of Lassa Fever Research.Current topics in microbiology and immunology · 2023Article
- Lassa Virus Genetics.Current topics in microbiology and immunology · 2023Article
- Lassa Fever Natural History and Clinical Management.Current topics in microbiology and immunology · 2023Article
- Lassa Virus Countermeasures.Current topics in microbiology and immunology · 2023Article
- Humoral and cellular immune responses to Lassa fever virus in Lassa fever survivors and their exposed contacts in Southern Nigeria.Scientific reports · 2022Article
- Evaluation of Three Clinical Prediction Tools to Predict Mortality in Hospitalized Patients with Lassa Fever.The American journal of tropical medicine and hygiene · 2022Article
- Pathogenicity and virulence mechanisms of Lassa virus and its animal modeling, diagnostic, prophylactic, and therapeutic developments.Virulence · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
38 authors at 8 institutions in 3 countries.
Funding
Abstract
Lassa fever, a hemorrhagic fever caused by Lassa virus (LASV), is endemic in West Africa. It is difficult to distinguish febrile illnesses that are common in West Africa from Lassa fever based solely on a patient's clinical presentation. The field performance of recombinant antigen-based Lassa fever immunoassays was compared to that of quantitative polymerase chain assays (qPCRs) using samples from subjects meeting the case definition of Lassa fever presenting to Kenema Government Hospital in Sierra Leone. The recombinant Lassa virus (ReLASV) enzyme-linked immunosorbant assay (ELISA) for detection of viral antigen in blood performed with 95% sensitivity and 97% specificity using a diagnostic standard that combined results of the immunoassays and qPCR. The ReLASV rapid diagnostic test (RDT), a lateral flow immunoassay based on paired monoclonal antibodies to the Josiah strain of LASV (lineage IV), performed with 90% sensitivity and 100% specificity. ReLASV immunoassays performed better than the most robust qPCR currently available, which had 82% sensitivity and 95% specificity. The performance characteristics of recombinant antigen-based Lassa virus immunoassays indicate that they can aid in the diagnosis of LASV Infection and inform the clinical management of Lassa fever patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.